In conclusion, we believe that the combination of CDX2, HTR2B, FRMD6, and ZEB1 immunohistochemistry and MSI analysis can be a prognostic factor for early-stage SACs. Here, FRMD6 is linked to Charlevoix-Saguenay spastic ataxia.